help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on May 29, 2008, doi:10.1164/rccm.200801-131OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200801-131OCv1
178/3/276    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, H. R.
Right arrow Articles by Williams, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, H. R.
Right arrow Articles by Williams, M. D.
American Journal of Respiratory and Critical Care Medicine Vol 178. pp. 276-282, (2008)
© 2008 American Thoracic Society
doi: 10.1164/rccm.200801-131OC


Original Article

Interleukin-8 as a Stratification Tool for Interventional Trials Involving Pediatric Septic Shock

Hector R. Wong1, Natalie Cvijanovich2, Derek S. Wheeler1, Michael T. Bigham1, Marie Monaco1, Kelli Odoms1, William L. Macias3 and Mark D. Williams3

1 Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; 2 Division of Critical Care Medicine, Children's Hospital and Research Center Oakland, Oakland, California; and 3 Eli Lilly Research Laboratories, Indianapolis, Indiana

Correspondence and requests for reprints should be addressed to Hector R. Wong, M.D., Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039. E-mail: hector.wong{at}cchmc.org

Rationale: Interventional clinical trials involving children with septic shock would benefit from an efficient preenrollment stratification strategy.

Objectives: To test the predictive value of interleukin (IL)-8 for 28-day mortality in pediatric septic shock.

Methods: A training data set (n = 40) identified a serum IL-8 of greater than 220 pg/ml as having a 75% sensitivity and specificity for predicting 28-day mortality. This cutoff was then subjected to a series of validation steps.

Measurements and Main Results: Subjects were drawn from two large, independent pediatric septic shock databases. Prospective application of the IL-8 cutoff to validation data set 1 (n = 139) demonstrated 78% sensitivity and 64% specificity for 28-day mortality. A serum IL-8 level of 220 pg/ml or less, however, had a negative predictive value for 28-day mortality of 95% in validation data set 1, which was subsequently applied to an independently generated data set of children with septic shock (validation set 2, n = 193). A serum IL-8 level of 220 pg/ml or less had a negative predictive value for 28-day mortality of 94% when applied to validation set 2.

Conclusions: A serum IL-8 level of 220 pg/ml or less, obtained within 24 hours of admission, predicts a high likelihood of survival in children with septic shock. We propose that IL-8 can be used to exclude such patients from interventional clinical trials and ultimately derive a study population with a more favorable risk to benefit ratio when subjected to a study agent.

Key Words: pediatrics • septic shock • biomarkers • interleukin-8 • stratification


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
The development of an effective biomarker would be a useful stratification tool for clinical studies involving children with septic shock.

What This Study Adds to the Field
Serum interleukin-8 serum level, obtained within 24 hours of admission, has a 95% negative predictive value for mortality in children with septic shock.

 



This article has been cited by other articles:


Home page
Proc Am Thorac SocHome page
K. R. Flaherty
Clinical Year in Review IV: Pediatric Pulmonary and Critical Care, Cystic Fibrosis, Asthma, and Pleural Disease
Proceedings of the ATS, September 15, 2009; 6(6): 506 - 511.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. G. Kallapur, T. J. M. Moss, R. L. Auten Jr., I. Nitsos, J. J. Pillow, B. W. Kramer, D. Y. Maeda, J. P. Newnham, M. Ikegami, and A. H. Jobe
IL-8 signaling does not mediate intra-amniotic LPS-induced inflammation and maturation in preterm fetal lamb lung
Am J Physiol Lung Cell Mol Physiol, September 1, 2009; 297(3): L512 - L519.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. A. Fowler, N. K. J. Adhikari, D. C. Scales, W. L. Lee, and G. D. Rubenfeld
Update in Critical Care 2008
Am. J. Respir. Crit. Care Med., May 1, 2009; 179(9): 743 - 758.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. T. Cornell, V. Hinkovska-Galcheva, L. Sun, Q. Cai, M. B. Hershenson, S. Vanway, and T. P. Shanley
Ceramide-dependent PP2A regulation of TNF{alpha}-induced IL-8 production in respiratory epithelial cells
Am J Physiol Lung Cell Mol Physiol, May 1, 2009; 296(5): L849 - L856.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2008 American Thoracic Society
  Tobacco